Citius Pharmaceuticals (CTXR) Income from Continuing Operations (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Income from Continuing Operations came in at 28109746.0 in Q1 2026, down 144.19% YoY from 63613578.85 in Q1 2025, and down 199.23% on a QoQ basis from 9393889.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Income from Continuing Operations data on file, last reported at 28109746.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 144.19% year-over-year to 28109746.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55451153.0 (down 27.64% YoY) and the FY2025 annual result came in at 39740269.0, down 0.8% from the prior year.
- Income from Continuing Operations declined to 28109746.0 in Q1 2026, from 9393889.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3593645.0 in Q4 2022 to a low of 28109746.0 in Q1 2026.
- A 5-year average of 10179534.18 and a median of 9231185.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 61.05% — and 2023, when it plunged 156.88%.
- Tracing CTXR's Income from Continuing Operations over 5 years: stood at 3593645.0 in 2022, then sank by 156.88% to 9231185.0 in 2023, then slipped by 11.38% to 10281246.0 in 2024, then grew by 8.63% to 9393889.0 in 2025, then slumped by 199.23% to 28109746.0 in 2026.
- The last three Income from Continuing Operations figures came in at 28109746.0 (Q1 2026), 9393889.0 (Q4 2025), and 8743646.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | -11.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.11 Mn |
| Dec 31, 2025 | -9.39 Mn |
| Sep 30, 2025 | -8.74 Mn |
| Jun 30, 2025 | -9.20 Mn |
| Mar 31, 2025 | -11.51 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -11.08 Mn |
| Jun 30, 2024 | -10.57 Mn |
| Mar 31, 2024 | -8.54 Mn |
| Dec 31, 2023 | -9.23 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -10.53 Mn |
| Dec 31, 2022 | -3.59 Mn |
| Sep 30, 2022 | -7.41 Mn |
| Jun 30, 2022 | -8.86 Mn |
| Mar 31, 2022 | -7.56 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Sep 30, 2021 | -5.13 Mn |
| Jun 30, 2021 | -15.01 Mn |